An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
NCT05106387
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Disease (CKD)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Regeneron Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Cedars-Sinai Medical Center · Los Angeles, CA
- University of California Irvine · Orange, CA
- Connie Frank Transplant Center at UCSF · San Francisco, CA
Illinois · 1
- Comprehensive Transplant Center · Chicago, IL
Maryland · 1
- John Hopkins Hospital · Baltimore, MD
Minnesota · 1
- University of Minnesota · Minneapolis, MN
New York · 1
- New York University Langone Health · New York, NY
Pennsylvania · 1
- Penn Transplant Institute · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.